Trial
NCT05564338
Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma
Phase IIIWITHDRAWNREGULATORYConfidence: MEDIUM
Sponsor
BeiGene
Collaborators
—
Condition
Hepatocellular Carcinoma
Intervention
Sitravatinib
Why stopped
Study has voluntarily discontinued due to a change in the company-level development strategy and is not because of any safety concern or the request from any health authority worldwide.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-06-07